Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Martin A. Pule"'
Autor:
Pedro Horna, Matthew J. Weybright, Mathieu Ferrari, Dennis Jungherz, YaYi Peng, Zulaikha Akbar, F. Tudor Ilca, Gregory E. Otteson, Jansen N. Seheult, Janosch Ortmann, Min Shi, Paul M. Maciocia, Marco Herling, Martin A. Pule, Horatiu Olteanu
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The diagnosis of leukemic T-cell malignancies is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. Recently developed therapeutic antibodies specific for the
Externí odkaz:
https://doaj.org/article/48857f99de054473875e959f04e0679a
Autor:
Giulia Agliardi, Anna Rita Liuzzi, Alastair Hotblack, Donatella De Feo, Nicolás Núñez, Cassandra L. Stowe, Ekaterina Friebel, Francesco Nannini, Lukas Rindlisbacher, Thomas A. Roberts, Rajiv Ramasawmy, Iwan P. Williams, Bernard M. Siow, Mark F. Lythgoe, Tammy L. Kalber, Sergio A. Quezada, Martin A. Pule, Sonia Tugues, Karin Straathof, Burkhard Becher
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Glioblastoma multiform (GBM) is a common and aggressive type of primary brain cancer that currently has no effective therapy. Here, the authors show, using a mouse GBM model and EGFRvIII-targeting chimeric antigen receptor (CAR)-T cells, that Intratu
Externí odkaz:
https://doaj.org/article/b2005a4f42464b199597399076f130a8
Autor:
Francesco Nannini, Lenart Senicar, Farhaan Parekh, Khai J. Kong, Alexander Kinna, Reyisa Bughda, James Sillibourne, Xihao Hu, Biao Ma, Yuchen Bai, Mathieu Ferrari, Martin A. Pule, Shimobi C. Onuoha
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Phage display technology in combination with next-generation sequencing (NGS) currently is a state-of-the-art method for the enrichment and isolation of monoclonal antibodies from diverse libraries. However, the current NGS methods employed for seque
Externí odkaz:
https://doaj.org/article/0fb7f6dbbb2349a594c6d571d3da7749
Autor:
Ilaria M. Michelozzi, Eduardo Gomez-Castaneda, Ruben V. C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A. Pule, Christopher J. Tape, Sergi Castellano, Persis J. Amrolia, Alice Giustacchini
Publikováno v:
Blood advances.
We recently described a low-affinity second-generation CD19 chimeric antigen receptor (CAR) CAT that showed enhanced expansion, cytotoxicity, and antitumor efficacy compared with the high-affinity (FMC63-based) CAR used in tisagenlecleucel, in precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed2f0f05acff2656fbf94aef8ae3ab2
https://pubmed.ncbi.nlm.nih.gov/36453632
https://pubmed.ncbi.nlm.nih.gov/36453632
Autor:
Paul M. Maciocia, Patrycja A. Wawrzyniecka, Nicola C. Maciocia, Amy Burley, Thaneswari Karpanasamy, Sam Devereaux, Malika Hoekx, David O’Connor, Theresa Leon, Tanya Rapoz-D’Silva, Rachael Pocock, Sunniyat Rahman, Giuseppe Gritti, Diana C. Yánez, Susan Ross, Tessa Crompton, Owen Williams, Lydia Lee, Martin A. Pule, Marc R. Mansour
Publikováno v:
Blood. 140(1)
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of immature T lymphocytes, associated with higher rates of induction failure compared with those in B cell acute lymphoblastic leukemia. The potent immunotherapeutic approaches a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a21b0af31f322e39878b84f7fcf2d7c0
https://pubmed.ncbi.nlm.nih.gov/35797017
https://pubmed.ncbi.nlm.nih.gov/35797017
Autor:
Ilaria M. Michelozzi, Eduardo Gomez Castaneda, Ruben V.C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A. Pule, Christopher J. Tape, Sergi Castellano, Persis J. Amrolia, Alice Giustacchini
We recently described a low-affinity second-generation CD19 chimeric antigen receptor (CAR) CAT that showed enhanced expansion, cytotoxicity, and anti-tumour efficacy compared to the high-affinity (FMC63 based) CAR used in Tisagenlecleucel, in pre-cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b79f0bbfa6bbb39f2b825d5e9d2ba484
https://doi.org/10.1101/2020.09.22.291831
https://doi.org/10.1101/2020.09.22.291831
Autor:
Sara, Ghorashian, Anne Marijn, Kramer, Shimobi, Onuoha, Gary, Wright, Jack, Bartram, Rachel, Richardson, Sarah J, Albon, Joan, Casanovas-Company, Fernanda, Castro, Bilyana, Popova, Krystle, Villanueva, Jenny, Yeung, Winston, Vetharoy, Aleks, Guvenel, Patrycja A, Wawrzyniecka, Leila, Mekkaoui, Gordon Weng-Kit, Cheung, Danielle, Pinner, Jan, Chu, Giovanna, Lucchini, Juliana, Silva, Oana, Ciocarlie, Arina, Lazareva, Sarah, Inglott, Kimberly C, Gilmour, Gulrukh, Ahsan, Mathieu, Ferrari, Somayya, Manzoor, Kim, Champion, Tony, Brooks, Andre, Lopes, Allan, Hackshaw, Farzin, Farzaneh, Robert, Chiesa, Kanchan, Rao, Denise, Bonney, Sujith, Samarasinghe, Nicholas, Goulden, Ajay, Vora, Paul, Veys, Rachael, Hough, Robert, Wynn, Martin A, Pule, Persis J, Amrolia
Publikováno v:
Nature medicine. 25(9)
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::253be259d2e882a0022b2d2318735d05
https://pubmed.ncbi.nlm.nih.gov/31520063
https://pubmed.ncbi.nlm.nih.gov/31520063
Autor:
Claire Roddie, Maeve A. O'Reilly, Juliana Dias Alves Pinto, Ketki Vispute, Fahetullah Syed, Lauren Nickolay, Yashma Pathak, Alexia Gali, Helen Lowe, Kim Champion, Graham Wheeler, Jo Olejnik, Maria Marzolini, Martin A. Pule, Karl S. Peggs
Publikováno v:
Cancer Research. 79:CT105-CT105
Introduction: CD19 CAR T therapy has advanced treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (B-ALL). However, several challenges remain including: (1) considerable toxicity of CD19 CAR therapy; (2) the need for long-term persist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c099275e7c75c0c8db36c3ea68c49b4
https://doi.org/10.1158/1538-7445.am2019-ct105
https://doi.org/10.1158/1538-7445.am2019-ct105
Publikováno v:
Angewandte Chemie (International Ed. in English)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c85013dfee8baa8cece7cb8973fcc60
http://europepmc.org/articles/PMC4738560
http://europepmc.org/articles/PMC4738560
Autor:
Harry Dolstra, Claire Roddie, Martin A Pule, Vedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background AUTO1 is a fast off-rate CD19-targeting chimeric antigen receptor (CAR), which has been successfully tested in adult lymphoblastic leukemia. Tscm/Tcm-enriched CAR-T populations confer the best expansion and persistence, but Tscm/Tcm number
Externí odkaz:
https://doaj.org/article/304fa86b5512400a84f30e4d82b38677